These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19227560)

  • 1. Study supports use of Isentress for first line treatment.
    Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560
    [No Abstract]   [Full Text] [Related]  

  • 2. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
    Proj Inf Perspect; 2009 Mar; (48):6. PubMed ID: 19492458
    [No Abstract]   [Full Text] [Related]  

  • 3. Isentress gets another good grade.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):9. PubMed ID: 19043877
    [No Abstract]   [Full Text] [Related]  

  • 4. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
    [No Abstract]   [Full Text] [Related]  

  • 6. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 11. Study explains Isentress' excellent resistance profile.
    Proj Inf Perspect; 2008 Dec; (47):3. PubMed ID: 19226674
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

  • 13. One-on-one with Joe Eron, M.D. An update on Isentress (raltegravir) data, including some unexpected results. Interview by Jeff Berry.
    Eron J
    Posit Aware; 2009; 20(3):46-7. PubMed ID: 19492451
    [No Abstract]   [Full Text] [Related]  

  • 14. [Raltegravir: initially as effective as standard therapy].
    Warpakowski A
    MMW Fortschr Med; 2010 Apr; 152(17):49. PubMed ID: 20509262
    [No Abstract]   [Full Text] [Related]  

  • 15. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 16. Isentress equal to Sustiva in first line therapy.
    Proj Inf Perspect; 2009 Mar; (48):6-7. PubMed ID: 19496211
    [No Abstract]   [Full Text] [Related]  

  • 17. Raltegravir. In HIV-infected in children at least 2 years of age. Only after prior treatment failure.
    Prescrire Int; 2014 Sep; 23(152):206. PubMed ID: 25325117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
    Rowley M
    Prog Med Chem; 2008; 46():1-28. PubMed ID: 18381123
    [No Abstract]   [Full Text] [Related]  

  • 19. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 20. Trial will evaluate a once-daily dose of raltegravir.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.